^
    7d
    AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer (clinicaltrials.gov)
    P1, N=46, Not yet recruiting, Jonsson Comprehensive Cancer Center
    New P1 trial
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • oxaliplatin • irinotecan • Yutuo (zimberelimab) • leucovorin calcium • fluorouracil topical
    11d
    Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=17, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=32 --> 17
    Enrollment closed • Enrollment change
    |
    TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    TP53 mutation
    |
    Venclexta (venetoclax) • azacitidine • adrixetinib (Q702)
    14d
    Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=4, Terminated, The University of Texas Health Science Center at San Antonio | N=44 --> 4 | Trial completion date: Sep 2027 --> May 2026 | Recruiting --> Terminated | Trial primary completion date: Sep 2027 --> May 2026; Investigational drug limitations
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • erlotinib • docetaxel • bemcentinib (BGB324) • Vonjo (pacritinib)
    14d
    Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, University of Wisconsin, Madison | Trial completion date: Aug 2027 --> Oct 2026
    Trial completion date • Checkpoint inhibition
    |
    Keytruda (pembrolizumab) • INCB81776
    21d
    AXL receptor tyrosine kinase regulates Golgi organization and function via an adhesion-Arf1 signalling axis in breast and lung cancer cell lines. (PubMed, Biol Open)
    AXL is prominently localized to the Golgi and is displaced upon inhibition with R428, which disrupts Golgi organization...This impacts Golgi-associated functions, tubulin acetylation in MDAMB231 cells, and cell-surface glycosylation in A549 cells. Together, our findings identify an adhesion-AXL-AMPK-GBF1-Arf1 pathway governing Golgi organization and function in cancer cells.
    Preclinical • Journal
    |
    AXL (AXL Receptor Tyrosine Kinase)
    |
    bemcentinib (BGB324)
    22d
    Discovery of NTQ2494, a potent and orally bioavailable inhibitor of AXL kinase for the treatment of human tumors. (PubMed, Eur J Med Chem)
    NTQ2494 (5p) exhibited favorable ADMET properties and demonstrated significantly enhanced in vivo efficacy in an MV-4-11 xenograft model compared to TP-0903. NTQ2494 is currently under Phase I clinical evaluation for the treatment of advanced hematological malignancies and solid tumors.
    Journal
    |
    AXL (AXL Receptor Tyrosine Kinase)
    |
    dubermatinib (TP-0903)
    29d
    Dual Blockade of PD-L1 and AXL: A Novel Immunotherapeutic Approach for Ovarian and Cervical Cancer. (PubMed, Iran J Allergy Asthma Immunol)
    In this study, we targeted PD-L1 using an siRNA and AXL using a blocker (R428) in OVACAR-3 and CaSki cells, ovarian and cervical cancer cell lines, respectively, in the following groups: Scramble-siRNA, PD-L1-siRNA, Scramble-siRNA in conjunction with R428, PD-L1-siRNA in conjunction with R428, R428 monotherapy and untreated controls. Cell viability was assessed by MTT assay after 48 hours of treatment, and cisplatin sensitization was evaluated in resistant OVACAR-3 cells...The results showed a significant decrease in cell proliferation, suppression of EMT-regulating genes, reduction of stemness in cancer cells, increased apoptosis and disruption of the cell cycle in the studied cell lines. These findings suggest that simultaneous blockade of PD-L1 and AXL could serve as a novel tumor-suppressive strategy, especially for cancer patients resistant to ICBs.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    AXL (AXL Receptor Tyrosine Kinase) • ANXA5 (Annexin A5)
    |
    cisplatin • bemcentinib (BGB324)
    2ms
    Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, University of Wisconsin, Madison | Recruiting --> Active, not recruiting
    Enrollment closed • Checkpoint inhibition
    |
    Keytruda (pembrolizumab) • INCB81776
    2ms
    AXL-Driven Stemness and Hedgehog Signaling in HER2-Positive Breast Cancer with Acquired Trastuzumab Resistance: Synergistic Potential of AXL and HER2 Co-Targeting. (PubMed, Life (Basel))
    These results emphasize the pivotal role of AXL in regulating both stemness and hedgehog signaling in HER2-positive breast cancer. The study suggests that targeting both AXL and HER2 could be a promising strategy to overcome trastuzumab resistance and improve treatment outcomes.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • AXL (AXL Receptor Tyrosine Kinase) • PTCH1 (Patched 1) • GLI1 (GLI Family Zinc Finger 1) • SOX2 • POU5F1 (POU Class 5 Homeobox 1) • GAS6 (Growth arrest specific 6) • NANOG (Nanog Homeobox)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • bemcentinib (BGB324)
    3ms
    KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer (clinicaltrials.gov)
    P2, N=60, Recruiting, Beijing Konruns Pharmaceutical Co., Ltd.
    New P2 trial
    |
    cisplatin • paclitaxel • Loqtorzi (toripalimab-tpzi) • KC1036
    3ms
    COAXIN: Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, University of Oklahoma | Trial completion date: Feb 2026 --> Oct 2026
    Trial completion date
    |
    Bavencio (avelumab) • batiraxcept (AVB-500)
    3ms
    ONO-7475-03: Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=78, Completed, Ono Pharmaceutical Co. Ltd | Active, not recruiting --> Completed | Trial completion date: Apr 2026 --> Jun 2025 | Trial primary completion date: Apr 2026 --> Jun 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Tagrisso (osimertinib) • tamnorzatinib (ONO-7475)